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Positron Emission Tomography 18F-Fluorodeoxyglucose
Uptake and Prognosis in Patients with Surgically Treated,
Stage I Non-small Cell Lung Cancer:
A Systematic Review
Viswam S. Nair, MD,* Yelena Krupitskaya, MD,† and Michael K. Gould, MD, MS*‡
Background: 18F-fluorodeoxyglucose (FDG) uptake holds potential
as a noninvasive biomarker in patients with non-small cell lung cancer
(NSCLC). We aimed to investigate the association between tumor FDG
uptake and survival in patients with surgically resected, stage I NSCLC.
Methods: We used systematic methods to identify studies for
inclusion, assess methodological quality, and abstract relevant data
about study design and results.
Results: Our literature search identified 1578 citations, of which nine
retrospective, cross-sectional studies met eligibility criteria. In all stud-
ies, higher degrees of FDG uptake in the primary tumor were associated
with worse overall or disease free survival after 2 to 5 years of
follow-up, but these differences were statistically significant in only five
studies. Across studies, the median overall or disease free survival was
70% for patients with higher FDG uptake compared with 88% for
patients with lower FDG uptake. In three studies that performed
multivariable analysis, the adjusted hazard of death or recurrence was
1.9 to 8.6 times greater in patients with higher FDG uptake.
Conclusion: Current evidence suggests that increasing tumor FDG
uptake is associated with worse survival in patients with stage I
NSCLC. FDG uptake has the potential to be used as a biomarker for
identifying stage I patients who are at increased risk of death or
recurrence and therefore could identify candidates for participation in
future trials of adjuvant therapy.
Key Words: Systematic review, Stage I, Non-small cell lung cancer,
FDG uptake, Standard uptake value, Prognosis, Survival, Outcome.
(J Thorac Oncol. 2009;4: 1473–1479)
Lung cancer is the second most common cancer in both menand women in the United States, and it remains the
number one cancer related cause of death, with over 160,000
people estimated to die of it during 2008 alone.1 Non-small
cell lung cancer (NSCLC) accounts for the majority of these
cases, and to date prognosis and therapy have been guided
chiefly by the Tumor, Node, Metastasis (TNM) staging sys-
tem. Although surgically treated patients with localized dis-
ease have the best prognosis, 5-year survival after resection in
patients with stage I disease approaches a modest 60%.2–6
18F-fluorodeoxyglucose (FDG) positron emission to-
mography (PET) imaging is widely used to determine TNM
stage in patients with NSCLC, altering the stage designation
and management in as many as 20 to 40% of patients.7–9 It is
based on the observation that metabolically active cells se-
lectively take up and trap fluoridated glucose, which then
undergoes nuclear decay that can be detected, localized, and
quantified.10 Furthermore, the intensity of FDG uptake has
been shown to correlate with tumor growth rates.11–14
Methods for quantifying FDG uptake include calculating
a standardized uptake value (SUV) or determining the metabolic
rate of glucose (MRglu) by means of kinetic studies or Patlak
analysis.15,16 SUV can be quantified as a mean value (based on
a region of interest ROI, which circumscribes the given
abnormality and is defined by a processing algorithm) or a
maximum value. In either case, uptake is quantified numeri-
cally after making adjustments for injected dose, body
weight, and background uptake. MRglu is used less com-
monly because of methodologic complexity.15,16
Given the imperfect nature of TNM staging, a number
of investigators have examined tumor FDG uptake as a prog-
nostic biomarker, with a recent review and meta-analysis con-
cluding that FDG uptake is negatively correlated with prognosis
in heterogeneous groups of patients with NSCLC.17,18 However,
studies included in these reviews were not limited to patients
with localized disease, and several studies of FDG uptake and
prognosis have been published in the interim. In theory, high
FDG uptake may define a subgroup of patients with localized
disease whose risk of recurrence and death might be large
enough to justify enrollment in trials of adjuvant therapy after
surgery. Accordingly, we performed a systematic review to
identify, appraise, and synthesize results from published stud-
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ies that examined the association between tumor FDG uptake
and prognosis in patients with stage I NSCLC.
METHODS
Patient Selection
We considered studies for inclusion if they examined
the association between tumor FDG uptake and survival in
newly diagnosed patients with a pathologic diagnosis of
NSCLC, enrolled at least 20 patients, and had a defined
endpoint of recurrence or death (Figure 1). Studies that
included patients with small cell carcinoma were eligible if at
least 90% of patients had NSCLC or separate results were
reported for NSCLC patients. Studies that included patients
who had received neoadjuvant therapy at the time of PET
imaging were excluded.
Search Strategy
An unrestricted language search strategy was devel-
oped by the authors and a professional librarian that queried
MEDLINE (from 1966 to August 2008), BIOSIS (from 1926
to August 2008), EMBASE (from 1947 to August 2008), and
Web of Science (from 1900 to August 2008) using the
following search terms:
Lung Cancer  FDG  Prognosis NOT Letter OR Case-
Report OR Editorial OR Animal-Only Lung cancer* tw
OR lung neoplasm* tw OR lung carcinoma* tw OR
pulmonary neoplasm* tw OR pulmonary cancer* tw
OR pulmonary carcinoma* tw OR ((lung* tw OR
pulmonary tw) AND (cancer* tw OR carcinoma* tw
OR malignan* tw OR eoplasm* tw OR tumors tw OR
tumor tw)) OR “Lung Neoplasms” mesh “18F-FDG”
tw OR “FDG-F18” tw OR FDG tw OR F18 tw OR
((F18 tw OR “fluorine 18” tw OR “F 18” tw OR 18F
tw) AND (fluorodeoxyglucose tw OR fludeoxyglucose
tw)) OR “2 Fluoro 2 deoxy D glucose” tw OR “2-
Fluoro-2-deoxyglucose” tw prognos* tw OR predict*
tw OR course tw OR “natural history” tw OR inci-
dence sh OR death* OR “models, statistical” mesh OR
cohort* tw OR diagnosed tw OR “first episode” tw
OR occur* tw OR recur* tw OR “long term” tw OR
prospective tw OR “mortality” mesh OR mortality sh
OR “follow-up studies” mesh.
We supplemented searches of electronic databases by review-
ing the reference lists of retrieved articles.
Data Abstraction
One physician (V.S.N.) reviewed titles and abstracts of all
reports. Reviews, editorials, and letters were excluded during the
initial review process. All relevant citations were English in
language. Two physicians (V.S.N., Y.K.) independently re-
viewed the full text of 58 potentially relevant articles to deter-
mine eligibility and study quality. In cases of discordance, a
FIGURE 1. Flow chart of included and excluded studies.
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third independent reviewer (M.K.G.) assessed eligibility. Qual-
ity criteria assessed study design, reporting of patient character-
istics, PET protocols, clinical follow-up, and statistical analysis.
Data abstraction was performed systematically with predeter-
mined variables of interest recorded for each article including
demographic characteristics, staging, histology, SUV acquisition
methods and values, timing of events, and outcomes.
Data Synthesis
To describe study and patient characteristics, we report
means, medians, and counts, depending on information pro-
vided in the primary studies. To describe outcomes, we report
estimates of percent survival with p values comparing groups
defined by high versus low degrees of FDG uptake. When
available, we also report adjusted hazard ratios (HRs) with
their 95% confidence intervals (CIs). Heterogeneity in study
methods and reporting of results precluded quantitative syn-
thesis. In some cases, time-to-event curves were analyzed by
the author (V.S.N.) to obtain numerical data not provided in
the study manuscript.
RESULTS
An initial search yielded 886 citations from MEDLINE,
386 citations from BIOSIS/Web of Science, and 306 citations
from EMBASE (Figure 1). Fifty-eight abstracts required
more thorough review to determine eligibility, and 30 of
these articles examined FDG uptake and prognosis in patients
with all stages of NSCLC. One article not initially retrieved
from our search was included after reviewing references of
included articles. One article was referenced incorrectly in
the EMBASE database and therefore could not be identi-
fied.19 Of these 30 eligible articles, we ultimately included
nine studies that examined the association between tumor
FDG uptake and survival in newly diagnosed patients with
stage I NSCLC who had surgery with curative intent.20–28
A total of 1166 patients with resected stage I NSCLC
were included in this analysis (Table 1). Only five of these
patients received adjuvant therapy. Mean/median age ranged
from 60 to 71 years, and women made up almost half of the
samples. Median duration of follow-up ranged from 26 to 46
months. All studies reported results for patients with patho-
logic stage I NSCLC except for Port et al.22 which reported
results for patients with clinical stage I NSCLC.
Study quality was suboptimal in several domains (Ta-
ble 2). None of the included studies enrolled participants
prospectively and just over half reported consecutive enroll-
ment. Patient characteristics were adequately described in
most studies. Reporting of technical details about image
acquisition, FDG uptake quantification, and statistical analy-
sis were all highly variable. PET scanner type, dosing, time to
acquisition, and serum glucose varied widely across included
studies (see Appendix, Supplemental Digital Content 1,
http://links.lww.com/JTO/A12). FDG uptake was quantified
as a SUV in all studies, however, technical details of how this
value was determined often were lacking (i.e., ROI process-
ing algorithm and SUV formula for calculation). Statistical
methods used to define threshold values for FDG uptake were
highly variable. Of the included studies, only four described
rigorous staging practices, varying from systematic nodal sam-
pling and complete homolateral nodal dissection to hilar/medi-
astinal nodal sampling.21,23,24,28 Many studies did not report
methods used to document recurrence, i.e., computed tomogra-
phy and/or PET, clinical status, or biopsy. Only a few studies
performed multivariable analysis to adjust for confounding.
Average dose of injected tracer ranged from 5 to 15
mCi. Seven studies used dedicated PET imaging, one study
used PET/computed tomography imaging, and one study did
not report imaging modality (see Appendix, Supplemental
Digital Content 1, http://links.lww.com/JTO/A12). Five stud-
ies used more than one scanner for their study and resolution
was usually not reported. Fasting was standard for all studies
and ranged from 4 to 12 hours, however, serum glucose
concentration was reported before image acquisition in only one
study. Time from injection dose to scan ranged from 40 to 60
minutes. Six studies reported the “brightest” pixel intensity
TABLE 1. Characteristics of Included Studies
Author Country
Enrollment
Period na Stage Ib
Resected
Stage I Ia
Adjuvant
Treatment
Agea,c
(yr)
Gender
M (%)
Median
Follow-Upa
Higashi et al.20 Japan 1994–2000 57 46 46 38 None 64 54 34d
Cerfolio et al.21 United States 2001–2004 315 141 141 59 None 66 57 26
Port et al.22 United States 2001–2004 64 64 60 64 None 66 40 N/A
Ohtsuka et al.23 Japan 2001–2005 98 98 98 63 None 60 57 31d
Raz et al.24 United States 1998–2004 36 36e 36 16 5 71 39 31
Downey et al.25 United States 2000–2004 487 380 380 249 None 69 47 26
Gauger et al.26 United States 1992–2004 194 194f 194 125 None 67 44 33
Goodgame et al.27 United States 1999–2003 136 136 136 77 None 67 N/A 46
Hanin et al.28 Belgium N/A–2006 96 75 75 34 None 65 76 45d
Totals: 1483 1170 1166 725
a Represents data for all NSCLC from study, not just stage I NSCLC.
b All studies reported results of pathologic staging, except Port et al.
c Mean or median are reported depending on data that was provided and age for Ohtsuka was reported as follows: 66% of patients were 60 yr or older and 34% of patients were
younger than 60 yr.
d Mean reported instead.
e All were BAC and were treated as stage I, however, 4/36 were “multifocal.”
f Three patients were stage I “X” and only 173 of 194 of these patients had SUV data available for analysis.
N/A, not available; NSCLC, non-small cell lung cancer; SUV, standardized uptake value; BAC, bronchioloalveolar carcinoma.
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of the given ROI to quantify measurement of FDG uptake
(SUVmax). The remaining three studies used a ROI circum-
scribing the tumor to calculate an average SUV, although only
two studies described their processing algorithm in detail.
The most common methods used to determine an SUV
threshold were dichotomizing at the median (4 of 9) and the
method of log ranks (3 of 9). Two studies used an arbitrary
definition of PET positivity to dichotomize at a SUVmax of
2.5.29 Accordingly, the threshold value for FDG uptake var-
ied across studies from 2.5 to 10.
Methods for time-to-event analysis varied (Table 3).
Five studies measured survival time from the date of opera-
tion, two from the date of PET scan, and two did not report
this information. Five studies used overall survival (OS) as an
endpoint and four studies used disease-free survival (DFS) as
an endpoint with right censoring ranging from 2 to 5 years.
Five of nine studies reported that survival or disease free
survival was significantly worse in patients with higher degrees
of FDG uptake, including three of five studies that examined OS
and two of four studies that examined DFS (Table 3). In the
other four studies, there was a trend toward better outcomes in
patients with lower FDG uptake that was not statistically signif-
icant in two of the studies and not formally tested in the two
other studies. Median OS/DFS in the high FDG uptake groups
was 70% (range 17–87%) compared with 88% (range 74–
100%) in the low FDG uptake groups.
Three studies reported results of multivariable analyses
for patients with stage I NSCLC (Table 3) after adjusting for
histology (three studies), T stage (two studies), and age (one
study). In these studies, the adjusted hazard of death or
disease recurrence was 1.9 to 8.6 times greater in patients
with high FDG uptake, although the results were not statis-
tically significant in one study and the confidence intervals
were very wide in two studies.
Four studies reported separate analyses for patients with
stage Ia NSCLC, and survival was significantly worse for
patients with higher FDG uptake in two of these studies (Table
4). Patients with higher degrees of FDG uptake had worse
survival in two of three studies that reported separate results for
patients with stage Ib NSCLC (Table 4). Two studies analyzed
patients with resected, stage II NSCLC independently. One
showed a significant difference in survival based on FDG
uptake, whereas the other showed a nonsignificant trend toward
improved survival with lower FDG uptake (Table 5).21,28
DISCUSSION
Identifying patients with localized NSCLC who have a
poor prognosis remains a priority in clinical oncology given
their high 5-year mortality despite resection. This review is
the first to synthesize the existing data regarding the associ-
ation between FDG uptake and prognosis in patients with
surgically treated, stage I NSCLC. Although substantial het-
erogeneity across studies precluded us from performing a
formal, quantitative synthesis, we found that higher FDG
uptake in the primary tumor was significantly associated with
a worse prognosis in five of nine studies that reported out-
come for patients with resected, stage I NSCLC.
Although patients with higher degrees of FDG uptake had
a worse prognosis in all included studies, the magnitude, and
statistical significance of this finding varied across studies that
appeared to be similar in design. For example, studies by
Higashi et al. and Gauger et al. applied similar thresholds for
FDG uptake, but Higashi et al. found large differences in DFS at
5 years, whereas Gauger et al. found differences in 5-year DFS
that were small in magnitude and not statistically significant
(Table 3). The study by Higashi et al. had more patients with
stage Ia NSCLC (83% versus 55%) and more patients with
bronchioloalveolar cell carcinoma (28% versus 5%), perhaps
explaining a lower risk of recurrence in patients with low grade
FDG uptake in this study. However, Raz et al. found large
differences in OS stratified by FDG uptake at 3 years in a sample
that was composed entirely of patients with bronchioloalveolar
carcinoma. Downey et al. was the largest study included in our
review, and although there was no significant difference in OS
TABLE 2. Quality Analysis of Included Studies
Study Criteria Percent Studies
Study design
Prospective enrollment 0
Consecutive enrollment 56
Representative sample of well-defined patients 100
Patient characteristics described
Age 89
Gender 89
Smoking status 22
Histology 100
Stage 100
Staging methods 44
Systematic staging 22
Nonsystematic 22
Treatment 67
PET protocol
PET model specified 67
Fasting specified 44
Adjusted for weight 44
Serum glucose reported 11
Injection dose reported 56
Acquisition time from injection reported 56
Volumetric “region of interest” defined 22
SUV formula described 33
Follow-up
Survival/recurrence measured from date of PET scan 22
Time from PET to surgery/treatment specified 33
Fewer than 5% lost to follow-up 89
Reasons for lack of follow-up reported 11
Surveillance for disease recurrence described 44
Mean duration of follow-up at least 12 mo 100
Statistical analysis
Statistical methods described 100
Multivariate analysis (with adjustment for) 33
Age 11
T stage 22
Histology 33
Treatment 33
Outcome clearly specified and objectively defined 100
SUV, standardized uptake value; PET, positron emission tomography.
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based on FDG uptake alone, the combination of adenocarci-
noma, smaller tumor size, and low FDG uptake analyzed to-
gether identified a subgroup of patients with a favorable prog-
nosis. Although reasons for discordant findings across the nine
included studies are not readily apparent, heterogeneity in stag-
ing methods and histologic subtypes could be partly responsible.
We attempted to limit heterogeneity in study methods
by restricting our analysis to patients with surgically treated,
stage I NSCLC. Posthoc, we identified additional data from
our search that examined the effect of FDG uptake on
survival for patients with early-stage NSCLC who had sur-
gical resection with curative intent (Table 5).21,28,30–33 These
data suggest similar between-group differences in survival for
patients with low versus high FDG uptake.
A recent review by de Geus-Oei et al.17 examined FDG
uptake and prognosis in patients with all stages of NSCLC for
11 studies from 1998 to 2006. All 11 studies reported a
significant association between FDG uptake and prognosis,
although adjustments for potential confounders were not
reported. A meta-analysis from 2008 by the European Lung
Cancer Working Party identified 13 studies examining FDG
uptake and prognosis for patients with NSCLC between 1998
and 2005.18 In patients with stage I to III disease, they found
that the hazard of death was twice as great in patients with
high FDG uptake compared with those with low FDG uptake
(HR 2.09, 95% CI 1.54–2.83). Neither study performed a
separate analysis for patients with stage I disease.
Like our study, both the European Lung Cancer Work-
ing Party and de Geus-Oei et al. identified significant heter-
ogeneity in methods across studies. PET scanner resolution,
tumor volume, time to injection, and serum glucose are all
thought to affect FDG uptake.15,34–36 SUVmax may be more
reproducible than average SUV37 but much of the variability
in measuring FDG uptake cannot be corrected for and stan-
dardized protocols are required. The use of FDG-PET as an
additional determinant of prognosis in patients with NSCLC
requires implemenation of recommendations for standardiz-
ing patient preparation, image acquisition, reconstruction,
and processing. To facilitate these efforts, The European
Organization for Research and Treatment of Cancer PET
Study Group and the Cancer Imaging Program of the Na-
tional Cancer Institute have developed guidelines for the use
of FDG-PET imaging in determining prognosis.15
Studies included in this review had significant limitations.
Two of nine studies included fewer than 50 patients with stage
I NSCLC. All studies were retrospective and cross-sectional in
design and four performed posthoc analyses for patients with
stage I NSCLC. Six of nine studies did not adjust for potential
confounders. Four of nine studies determined FDG uptake
thresholds posthoc by selecting a favorable cutpoint, whereas the
remaining studies used a prespecified definition of median SUV
or “positive” FDG uptake as a threshold.
A critical question that remains unanswered in the treat-
ment of NSCLC is who should receive adjuvant therapy after
TABLE 3. FDG Uptake and Survival for Stage I NSCLC
Study n
Time
Zeroa
SUV Metric
Measured
SUV
Threshold
Survival
Metricb
Percent Survival
Multivariable
AnalysiscHigh SUV Low SUV p value
Higashi et al. 46 PET Meand 5 5 yr DFS 17 88e 0.001
Cerfolio et al. 141 Surgery Max 10 4 yr DFS 68 88e N/Af
Port et al. 64 N/A Max 2.5 3 yr OS 87 100 0.46
Ohtsuka et al. 98 N/A Max 3.3 2 yr DFS 75 95e 0.008 4.2 (0.8–21.5)
Raz et al. 36 Surgery Max 2.5 3 yr OS 49 95 0.005 8.6 (1.4–245)
Downey et al. 380 Surgery Max 4.3 2 yr OS 76 87e N/A
Gauger et al. 173 PET Meand 4.1 5 yr DFS 70 77g 0.21
Goodgame et al. 136 Surgery Meand 5.5 5 yr OS 53 74 0.006 1.9 (1.0–3.6)
Hanin et al. 75 Surgery Max 7.8 2 yr OS 80 95e 0.001
a Starting time point for survival analysis.
b Reported as OS (overall survival) or DFS (disease free survival).
c HR with 95% CI for 3 studies are shown: Ohtsuka adjusted for histology, Raz for histology and tumor size and Goodgame for histology, tumor size, and age.
d Determined from ROI (region of interest-an area circumscribing the area of FDG uptake but dependent on processing algorithm used).
e Extrapolated from survival curves provided within article.
f Reported a complete analysis for stage Ib NSCLC only, however, outcome for stage I NSCLC could be extrapolated from data provided.
g Calculated from data provided in Table 3 of this study.
N/A, not available; SUV, standardized uptake value; PET, positron emission tomography; FDG, 18F-fluorodeoxyglucose; NSCLC, non-small cell lung cancer; HR, hazard ratio;
CI, confidence interval.
TABLE 4. FDG Uptake and Survival in Stage Ia/Ib NSCLC
Stage Study n
Survival
Metric
Percent Survival
High SUV Low SUV p value
Ia Higashi et al. 38 5 yr DFS 25 85 0.001
Cerfolio et al. 59 4 yr DFS 70 100 NSa
Ohtsuka et al. 63 2 yr DFS 75 95 0.024
Downey et al. 249 2 yr OS 85 90 0.91
Ib Cerfolio et al. 82 4 yr OS 66 80 0.048b
Ohtsuka et al. 35 2 yr DFS 85 100 0.001
Downey et al. 131 2 yr OS 60 80 0.24
a Reported as not significant, however, full details of analysis not provided
within text.
b Survival based on dichotomized median SUVmax of 10.3.
NS, not significant; SUV, standardized uptake value; FDG, 18F-fluorodeoxy-
glucose; NSCLC, non-small cell lung cancer; OS, overall survival; DFS, disease
free survival.
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resection. The recently released lung adjuvant cisplatin evalua-
tion meta-analysis showed a 5.4% absolute overall survival
benefit for patients with resected NSCLC (stages I–III) who
received adjuvant chemotherapy.38 However, early chemother-
apy related mortality was substantial, with 342 of 2390 patients
dying from “non-lung cancer deaths” (HR 2.41, 95% CI 1.64–
3.55) within the first 6 months of follow-up. This translated to a
2% reduction in nonlung cancer survival for the chemotherapy
arm within the first 6 months. In addition, adjuvant chemother-
apy in patients with stage Ia NSCLC showed a trend toward
harm (HR 1.40, 95% CI 0.95–2.06). Although treatment of
patients with stage Ib NSCLC showed a nonsignificant trend
toward benefit in this meta-analysis (HR 0.93, 95% CI 0.78–
1.10), a recent follow-up of the CALGB 9633 trial showed a
diminution of survival benefit over time for these patients.39
Clearly, we need additional markers of prognosis be-
yond that of TNM staging alone for risk stratification and
selection of patients for adjuvant therapy. The degree of FDG
uptake in the primary tumor may define a subgroup of
patients with resected NSCLC and a poor prognosis who
would be appropriate candidates for enrollment in future
studies of adjuvant therapy. A “prognostic index” can be
envisioned that would take into account not only known
predictors of survival like TNM staging but also newer
modalities including biomarkers and functional imaging.
CONCLUSION
We identified nine studies that examined FDG uptake and
prognosis in patients with surgically treated, stage I NSCLC.
Although significant heterogeneity existed across studies in-
cluded in this review, we found substantial evidence that the
degree of FDG uptake in the primary tumor is associated with
prognosis in these patients. Future studies of FDG-PET and
prognosis in patients with surgically treated, stage I NSCLC
should enroll participants prospectively and consecutively, use
standardized protocols for FDG PET acquisition and processing,
adjust for potential confounders in the analysis (tumor size and
histology), and determine the optimal threshold value of
SUVmax that best identifies patients with an unfavorable prog-
nosis who might benefit from adjuvant therapy. In addition,
randomized trials of adjuvant chemotherapy seem to be justified
in patients with resected, stage I NSCLC who are at increased
risk of recurrence and death based on a high degree of FDG
uptake in the primary tumor.
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